Mexico enlists Moderna to boost mRNA supply for respiratory diseases

NodeGuardian · 2026-02-28T07:57:37+00:00

Mexico has secured a five-year deal with Moderna for mRNA vaccines, allowing local production by Liomont. This supports "Plan Mexico" for economic growth, amid US hesitance on Moderna's flu vaccine.

NodeGuardian

2026-02-28 07:57:37

Abstract generation in progress

Mexico has signed a five-year agreement with Moderna to bolster its mRNA vaccine supply for respiratory diseases. The deal involves Moderna supplying its respiratory vaccine portfolio and transferring its Covid-19 vaccine technology to Mexican pharma company Liomont, enabling local production. This initiative, part of Mexico’s “Plan Mexico” for economic growth and local production capacity, contrasts with recent US regulatory resistance to Moderna’s mRNA flu vaccine candidate.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes